[BOOK][B] Bibliography of research on ocean fronts, 1964-1984

LB Gilham, JJ Mika, DA Wiesenburg - 1985 - apps.dtic.mil
This report contains a bibliography of published papers describing research related to oceanic
fronts. The citations cover research on physical, chemical and biological ocenographic …

Tuberculosis screening before biologics—T-SPOT for all?

L Gilham, J France, A Stirling, S Bawa - The Journal of Rheumatology, 2011 - jrheum.org
There remains considerable uncertainty and widespread variation in practice throughout
rheumatology departments in the UK of screening methods for latent tuberculosis (LTB) prior to …

[PDF][PDF] NORDA Technical Note 303

LB Gilham, JJ Mika, DA Wiesenburg - 1985 - apps.dtic.mil
This report contains a bibliography of published papers describing research related to oceanic
fronts. The citations cover research on physical, chemical and biological oceanographic …

[HTML][HTML] Apabetalone downregulates factors and pathways associated with vascular calcification

D Gilham, LM Tsujikawa, CD Sarsons, C Halliday… - Atherosclerosis, 2019 - Elsevier
Background and aims Apabetalone is an inhibitor of bromodomain and extraterminal (BET)
proteins. In clinical trials, apabetalone reduced the incidence of major adverse cardiac …

[HTML][HTML] RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular …

D Gilham, S Wasiak, LM Tsujikawa, C Halliday… - Atherosclerosis, 2016 - Elsevier
High density lipoproteins (HDL), through activity of the main protein component apolipoprotein
AI (ApoA-I), can reduce the risk of cardiovascular disease (CVD) by removing excess …

[HTML][HTML] Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208)

S Wasiak, D Gilham, LM Tsujikawa, C Halliday… - Journal of …, 2017 - Springer
Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease
(CVD) that targets BET proteins. Through transcriptional regulation RVX-208 modulates …

Clinical progression of cats with early‐stage chronic kidney disease fed diets with varying protein and phosphorus contents and calcium to phosphorus ratios

…, JC Coltherd, J Atwal, M Gilham… - Journal of Veterinary …, 2021 - Wiley Online Library
Background Dietary protein and phosphorus (P) restriction is the mainstay for nutritional
management of chronic kidney disease (CKD). However, adequate restriction levels for cats …

[HTML][HTML] Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment

D Gilham, S Wasiak, BD Rakai, L Fu, LM Tsujikawa… - Biomedicines, 2023 - mdpi.com
Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney
disease (CKD). Apabetalone is an orally available inhibitor of bromodomain and extraterminal (…

Clinical Grade manufacture of CYAD-101, a NKG2D-based, First in Class, non–gene-edited allogeneic CAR T-Cell therapy

…, E Gauthy, S Agaugué, DE Gilham… - Journal of …, 2022 - journals.lww.com
Allogeneic chimeric antigen receptor (CAR) T holds the promise of taking this therapeutic
approach to broader patient populations while avoiding the intensive manufacturing demands …

[HTML][HTML] Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells

CD Sarsons, D Gilham, LM Tsujikawa, S Wasiak, L Fu… - Biomedicines, 2023 - mdpi.com
Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate
expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream …